discount wide manag deliv
achiev guidanc likelihood acceler
suggest setup remain favor pipelin driven
acceler biggest question catalyst
futur perform pt
solid quarter bottom line surpris report revenu
vs mse repres organ growth pt
top end guidanc pt mse reflect momentum stabil
preview face favor setup quarter given low
organ growth bar widen valuat gap versu peer ep upsid
mse reflect higher revenu better margin
ep guidanc rais
rais midpoint better perform interest expens discuss
oper margin expand bp y/i constant currenc basi
sg y/i first time year convers
compar across though manag continu target
convers rate lrp pleas see exhibit reconcili result
could smooth sail held organ growth guidanc
unchang year adjust guidanc modestli
suggest last quarter mute diabet
outlook still impli pt momentum improv improv
mitg fy guidanc impli top-line growth improv particularli
cvg diabet given sever product catalyst see easier comp
highest hurdl year even in-lin perform suggest
perform second half stabl momentum suggest outlook
achiev conserv beyond manag expect top line
momentum build launch convert revenu like
becom next debat stock
reconcil ep guidanc conserv manag rais ep
guidanc rais midpoint break
come today ep beat off-set fx impact
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
revers throughout year previous disclos lower interest
expens per quarter contribut addit
ep see note light histor issu drive consist
leverag confid sg incent plan impact
definit posit assum gross margin y/i
reflect fx ebit guidanc look conserv given bp report
expans impli bp drive guidanc call
bp y/i improv model bp oper margin improv
even though believ manag like invest materi upsid
new product launch
matter pipelin wrote quarter comp product
launch signific driver back half acceler eas
headwind potenti dcb steril modest pipelin contribut
tavr play role materi impact
surgic robot within mitg expect launch ex-u later
fiscal year await septemb analyst day better
understand system function structur importantli
launch time major market clinic path us commerci
sell strategi financi implic
cvg evolut improv suggest low-risk tavr earli inflect
manag comfort mid teen sustain perform given
recent low-risk approv ncd expans upcom launch includ
evolut follow reveal linq insert
cardiac monitor micra av transcathet pace system later
diabet expect weak point remain weak
product cycl sync strengthen
competitor next catalyst
rtg mazor pull brought back market separ
reiter interstim micro launch europ
spring us launch follow coupl month late
earli believ continu strength mazor coupl
interstim sens db platform launch drive acceler
pleas see devic deriv note greater detail around
competit landscap product
acceler consist execut pipelin remain key
perform bia posit prior last quarter given
remov guidanc headwind conserv outlook emerg pipelin
quarter break new ground organ growth
encourag margin perform given discount peer achiev
outlook still see setup favor growth improv like
continu follow remaind year view
consist execut durabl top bottom line perform
key becom posit essenc sustain outstand
question await emerg trend late rais
price target new ep reflect
discount large-cap peer
execut messag narrow discount
execut messag narrow discount
deriv base case scenario price target reflect
base-cas ep discount larg cap peer
bull case ep
bull case ep
reset expect execut organ growth trend
sustain new launch off-set competit headwind ep growth
doubl digit aggress capit deploy drive upsid
base case ep
base case ep
total return profil long-term profil mid-singl digit
organ growth bp margin expans high-singl digit ep
growth total return profil howev lower return profil
deceler lead discount versu peer
bear ep
bear ep
end market slow take top-line organ growth fall
manag mid-singl digit guidanc underli leverag harder
come given lower growth earn growth reach mid upper
total return profil achiev
consist organ sale growth
least bp ebit margin expans
return back
see organ revenu guidanc
achiev potenti conserv given
comp product pipelin
drive bp annual margin expans
top-line growth estim bp
top-line growth contribut ep
margin estim bp ebit
margin drive ep
new product launch uptak high
intelli neurosurgeri neurovascular
ration margin
risk achiev price
db tavr dcb linq
slowdown acceler emerg
less repurchas activ materi
million except ep
good sold
million
million
million
million
million
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
depreci amort
net chg work capit
net provid oper activ
acquisit net cash acquir
net use invest activ
chang debt
chang equiti net tax benefit
begin period
end period
dollar million except per share data
prepaid expens current asset
addit paid capit
accumul non-own chang equiti
receiv employe stock ownership plan
